The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
 
Chihiro Kosugi
No Relationships to Disclose
 
Hirohiko Kamiyama
No Relationships to Disclose
 
Yoichiro Yoshida
No Relationships to Disclose
 
Hiroshi Yoshida
No Relationships to Disclose
 
Keiichiro Ishibashi
No Relationships to Disclose
 
Keisuke Ihara
No Relationships to Disclose
 
Makoto Takahashi
No Relationships to Disclose
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Hiromichi Sonoda
No Relationships to Disclose
 
Kazuhiko Yoshimatsu
No Relationships to Disclose
 
Atsuko Fukazawa
No Relationships to Disclose
 
Akihisa Matsuda
No Relationships to Disclose
 
Satoru Yamaguchi
No Relationships to Disclose
 
Hideyuki Ishida
No Relationships to Disclose
 
Suguru Hasegawa
No Relationships to Disclose
 
Takeshi Yamada
Research Funding - Taiho Pharmaceutical (Inst)
 
Kazuo Narushima
No Relationships to Disclose
 
Kiyohiko Shuto
No Relationships to Disclose
 
Kazuhiro Sakamoto
No Relationships to Disclose
 
Keiji Koda
No Relationships to Disclose